Pharmacokinetics of alectinib and its metabolite M4 in a patient with advanced lung adenocarcinoma undergoing hemodialysis: A case report

Abstract This study presents the first detailed pharmacokinetic data of alectinib and its metabolite M4 in a patient with anaplastic lymphoma kinase (ALK)‐rearranged lung adenocarcinoma undergoing hemodialysis. When the patient was administered a daily 300 mg bid dose of alectinib, the maximal obser...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Ji Eun Park, Young‐Ran Yoon, Chang Ho Kim, Jaehee Lee
Format: Artigo
Sprache:Inglês
Veröffentlicht: Wiley 2022-04-01
Schriftenreihe:Thoracic Cancer
Schlagworte:
alectinib
ALK rearrangement
lung cancer
M4
pharmacokinetics
Online Zugang:https://doi.org/10.1111/1759-7714.14357
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge